What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Black triangle. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/16/1143/002, EU/1/16/1143/001, EU/1/16/1143/003.

Lartruvo 10 mg/mL concentrate for solution for infusion

Package leaflet: Information for the user

Lartruvo® 10 mg/mL concentrate for solution for infusion


▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Lartruvo is and what it is used for
2. What you need to know before you are given Lartruvo
3. How you are given Lartruvo
4. Possible side effects
5. How to store Lartruvo
6. Contents of the pack and other information

1. What Lartruvo is and what it is used for

Lartruvo contains the active substance olaratumab, which belongs to a group of medicines called monoclonal antibodies.

Olaratumab recognises and attaches specifically to a protein known as platelet-derived growth factor receptor-α (PDGFR-α). PDGFR-α is found in large amounts on some cancer cells where it stimulates the cells to grow and divide. When olaratumab attaches to PDGFR-α it may prevent cancer cell growth and survival.

Lartruvo is used in combination with another anti-cancer medicine called doxorubicin for the treatment of adults with advanced soft tissue sarcoma who have not been previously treated with doxorubicin. Soft tissue sarcoma is a cancer that starts in the soft tissues, such as the muscles, fat, cartilage and blood vessels.

2. What you need to know before you are given Lartruvo

You must not be given Lartruvo

  • if you are allergic to olaratumab or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

You should tell your doctor about any of the following:

  • if you are receiving any treatment for heart disease or liver disease

Talk to your doctor or nurse immediately if the following applies to you (or you are not sure):

  • Infusion-related reaction

Infusion-related reactions may occur during treatment with Lartruvo. Such reactions may be allergic. Symptoms may include back pain, chest pain and/or tightness, chills, fever, flushing, difficulty in breathing and wheezing. In severe cases, you may experience very low blood pressure, feel faint, and experience breathing distress caused by narrowing of the airways, which could be life-threatening. Your doctor will give you other medicines before you receive Lartruvo to reduce the risk of infusion-related reactions. Your doctor or nurse will check for side effects during and after your infusion. If you have a severe infusion-related reaction, your doctor may recommend reducing the dose of Lartruvo or stop your treatment with Lartruvo. See section 4 for more details about infusion-related reactions which may occur during or after the infusion.

  • Bleeding

Lartruvo and doxorubicin may decrease your platelet count. Platelets help your blood to clot and a low platelet count may increase the risk of bleeding. If you experience significant bleeding, symptoms may include extreme tiredness, weakness, dizziness or changes in the colour of your stools. Your doctor will check your platelet count prior to treatment with Lartruvo.

  • Reduction in the number of white blood cells

Lartruvo and doxorubicin may decrease the number of white blood cells (including neutrophils). White blood cells are important for fighting infection. A low white blood cell count may increase your risk for infection. Your doctor will check your white blood cell counts prior to treatment with Lartruvo.

Children and adolescents

Lartruvo should not be given to patients under the age of 18 years because there is no information about how it works in this age group.

Other medicines and Lartruvo

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

Before starting treatment you must tell your doctor if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby.

Avoid getting pregnant while receiving this medicine and for at least 3 months after the last dose of Lartruvo as this medicine may harm your unborn child. Talk to your doctor about the best contraception for you.

It is not known whether olaratumab gets into breast milk and if the breast-fed infant is at risk of harm. Ask your doctor if you can breast-feed during or after treatment with Lartruvo.

Driving and using machines

It is not known if Lartruvo will affect your ability to drive. If you get any symptoms that affect your ability to concentrate and react, such as tiredness, do not drive or use machines until the effect goes away.

Lartruvo contains sodium

This medicine contains 22 mg sodium in each 19 mL vial and 57 mg sodium in each 50 mL vial. This should be taken into consideration if you are on a controlled sodium diet.

3. How you are given Lartruvo

A doctor experienced in the use of anti-cancer medicines will supervise your Lartruvo therapy.


You will be given medicines to reduce the risk of an infusion-related reaction before you receive Lartruvo.

Dose and administration

The recommended dose of Lartruvo is 15 mg per kilogram of your body weight on days 1 and 8 of each 3-week cycle. Lartruvo is given in combination with the medicine doxorubicin for up to 8 cycles and then it is given on its own. The number of infusions that you receive will depend on how well and for how long treatment with Lartruvo works and how well you feel. Your doctor will discuss this with you.

This medicine is given as an infusion into a vein via a drip. The drip lasts about 60 minutes.

Detailed instructions for your doctor or your nurse on how to prepare Lartruvo infusion are included at the end of this package leaflet (see ‘Handling instructions’).

Dose adjustments

During each infusion, your doctor or nurse will check for side effects. Your doctor may also give you a smaller dose or delay your dose of Lartruvo if you get serious side effects including a lowering of your white blood cell counts. If you have an infusion-related reaction during treatment, your doctor or nurse may slow down or stop your Lartruvo infusion.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the risks and benefits of your treatment.

The following side effects have been reported:

Infusion reactions

Lartruvo has been associated with infusion reactions (see section 2 “Warnings and precautions”). Tell your doctor or nurse immediately if you feel unwell during infusion. Below is a list of some typical symptoms associated with infusion reactions:

  • Feeling faint
  • Fever
  • Chills
  • Flushing
  • Shortness of breath

Other symptoms may occur as well (see section 2 “Warnings and precautions”). Your doctor may consider slowing the Lartruvo infusion or interrupting it to manage these symptoms.

Very common (may affect more than 1 in 10 people):

  • nausea
  • pain in your muscles, joints or bones (musculoskeletal pain)
  • low white blood cell counts (including neutrophils and lymphocytes which may increase the risk of infection)
  • pain or sores in your mouth or throat (mucositis)
  • vomiting
  • diarrhoea
  • headache
  • infusion-related reactions

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via


HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
website: www.hpra.ie


ADR Reporting

United Kingdom:

Yellow Card Scheme
website: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Lartruvo

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C).

Do not freeze or shake the vial.

Keep the vial in the outer carton to protect from light.

Infusion solution: After dilution and preparation, the medicine must be used immediately. If not used immediately, in-use storage times and conditions before use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C and up to an additional 8 hours at room temperature (below 25 °C). Do not freeze or shake the infusion solution. Do not administer the solution if you notice any particulate matter or discoloration.

This medicine is for single use only.

Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.

6. Contents of the pack and other information

What Lartruvo contains

  • The active substance is olaratumab. Each millilitre of the concentrate for solution for infusion contains 10 mg of olaratumab.
    Each 19 mL vial contains 190 mg of olaratumab.
    Each 50 mL vial contains 500 mg of olaratumab.
  • The other ingredients are mannitol, glycine, L-histidine monohydrochloride monohydrate, L-histidine, sodium chloride (see section 2 “Lartruvo contains sodium”), polysorbate 20 and water for injections.

What Lartruvo looks like and contents of the pack

Lartruvo concentrate for solution for infusion (sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow liquid supplied in a glass vial with an elastomeric stopper.

It is available in packs of:

  • 1 vial of 19 mL
  • 2 vials of 19 mL
  • 1 vial of 50 mL

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands


Lilly S.A.
Avda de la Industria, 30
28108 Alcobendas

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Eli Lilly and Company Limited
Tel: + 44-(0) 1256 315000

This leaflet was last revised in April 2017.

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.